FWIW I belive Dew/Don's concern is based upon the rate of patient enrollment per site - e.g. for EYEGUARD A they gave enrollent rate as (from memory) 1 patient per year in the US, 2 patients per year ex-US.
E.g. if at the end of the year they have 100 US sites, 60 non-US and 40 patients already enrolled it will take more than 1 more year to enroll all the 300 patients. Trial wouldn't be mature until 2H15. Sites alone are unlikely to allow them to meet the 2014 dates.
Market Data 
Markets 
AI
